PUSLINCH, ON / ACCESSWIRE / January 30, 2019 / Spruce Ridge Resources Ltd. (TSX-V: SHL) is pleased to announce that it has received the results of the last five diamond drill holes in a 10-hole program on its wholly-owned Great Burnt Copper-Gold Project in Newfoundland. The drilling was targeted at the Great Burnt Main Zone, with a view to filling gaps between previous drill holes, testing for possible extensions of the Main Zone, testing a newly identified target from a 2007 airborne EM survey, and retrieving samples for future metallurgical study prior to a planned Preliminary Economic Assessment (PEA). Results include 9.97 metres of 7.45% copper (Cu), including a 5.03 metre section grading 11.42 % Cu in drill hole GB18-06. The massive to semi-massive sulphide mineralization also carries low values in gold, silver, zinc and cobalt. The following table summarizes the results for all ten holes of the 2018 program. Location of 2018 diamond drilling and historical drilling can be found at the end of this news release.

Hole No.

From (metres)

To (metres)

Core Length

Cu
(%)

Zn
(%)

Co
(%)

Au
(g/t)

Ag
(g/t)

GB18-01
Includes
And

5.33
7.00
24.58

14.54
10.00
26.87

9.21
3.00
2.29

1.34
2.24
1.37

0.02
0.03
0.08

0.009
0.016
0.028

0.011
0.015
0.028

0.4
0.9
0.7

GB18-02

No significant mineralization

GB18-03
And
Includes

84.17
97.54
103.11

88.96
106.17
106.17

4.79
8.63
3.06

0.68
1.81
3.44

0.03
0.03
0.04

0.009
0.016
0.007

0.016
0.015
0.033

0.3
0.6
1.3

GB18-04

47.80

51.80

4.00

4.42

0.33

0.030

0.06

2.8

GB18-05
Includes

95.76
100.35

116.70
107.33

20.94
6.98

6.21
10.71

0.54
0.90

0.040
0.060

0.09
0.14

7.0
11.8

GB18-06
Includes

104.56
106.80

114.53
111.83

9.97
5.03

7.45
11.42

0.43
0.57

0.034
0.042

0.081
0.094

4.5
6.2

GB18-07

No significant mineralization

GB18-08

No significant mineralization

GB18-09
And

39.26
73.70

57.26
81.85

18.00
8.15

0.23
019

0.01
0.01

0.005
0.006

0.016
0.021

0.4
0.2

GB18-10

31.00

33.40

2.40

0.19

0.06

0.003

0.084

1.0

Much of the previous drilling on the Great Burnt Main Zone was carried out on sections with a regular 61-metre (200 feet) spacing. Like drill holes GB18-03, -04 and -05 (see press release 2018-01 of January 23, 2019), GB18-06 was drilled to test the zone between two sections where there had been no previous infill drilling. GB18-07 and 18-08 were drilled to test possible down-dip extensions of the Lower Zone. GB18-09 and -10 were drilled to test for a possible extension of the low-grade Stringer Zone to the south and down-dip. Both holes cut disseminated to locally stringery mineralization with lower grades than the Stringer Zone average.

“The results of GB18-05 and GB18-06, combined with the other holes drilled into the Great Burnt Main Zone in 2016 and 2018, lead us to suspect that a recalculation of the mineral resource could possibly lead to a significant increase in the copper grade” stated John A. Ryan, CEO of Spruce Ridge.

The road-accessible Great Burnt copper-gold deposit comprises three separate zones of volcanogenic massive sulphide (VMS) mineralization: The Main, Lower and Stringer Zones. A 2015 NI43-101 technical report by P&E Mining Consultants identified Indicated Mineral Resources in the Main and Lower Zones of 382,000 tonnes with an average grade of 2.68% Cu, plus Inferred Mineral Resources of 663,000 tonnes averaging 2.31% Cu. A “starter pit” outlined by P&E includes an Indicated Mineral Resource of 237,000 tonnes at 2.51% Cu.

The majority of the drilling that outlined the Great Burnt deposit was carried out by Asarco between 1950 and 1971, and core was not assayed for gold. Additional drilling by Celtic Minerals in 2001-2002 did include assaying for gold and zinc. Four holes drilled into the Main Zone by Spruce Ridge in 2016 yielded intercepts including (in hole GB16-09) 5.75 metres of 6.68% Cu, 0.94% Zn, 0.871 g/t Au and 6.20 g/t Ag and (in hole GB16-08) 7.50 metres of 9.45% Cu, 0.73% Zn, 0.364 g/t Au and 8.50 g/t Ag. There is however insufficient information to estimate average grades for metals other than copper.

In addition to the Great Burnt copper-gold deposit, the 3,700-hectare property covers the South Pond “A” Zone, 15 kilometres to the north, with an Indicated Mineral Resource of 47,000 tonnes at 1.38% Cu, plus an Inferred Mineral Resource of 166,000 tonnes of 1.30% Cu. Re-analysis of core in 1987 indicated potentially significant grades of gold in the South Pond “A” zone; again the data are insufficient to include a gold grade in resource estimates. The South Pond “B” Zone has been drill tested over a 1.2 kilometre length, with results including a 28.00 metre core length of 1.16 g/t Au and a 4.33 metre core length of 4.75 g/t Au.

The 2018 diamond drilling program at Great Burnt was carried out under the supervision of Brian Willett, P.Geo. The NQ-size core was quartered with a diamond saw; one quarter was sent for analysis, one quarter was retained as a witness, and half core was placed in vacuum-sealed bags to preserve its freshness for future metallurgical testing. Analyses were performed by Eastern Analytical of Springdale, NL. Gold was determined by fire assay on 30-gram splits; all other elements were analysed by ICP after aqua regia digestion, and overlimit analyses (i.e. over 1% Cu, 0.22% Zn, 0.055% Co and 6 g/t Ag) were repeated using assay procedures. Eastern Analytical is certified to ISO/IEC 17025 with accreditation to the assay methods used.

Acknowledgments

Spruce Ridge would like to thank the Government of Newfoundland and Labrador for approving the Great Burnt Program for 2018 JEA funding.

About Spruce Ridge Resources Ltd.

Spruce Ridge holds a 100% interest in the Great Burnt Copper/Gold Property in Central Newfoundland which covers a series of copper ± gold rich VMS deposits. In 2015, Spruce Ridge optioned its Viking/Kramer gold properties in Western Newfoundland to Anaconda Mining Inc. The Company also has a 50% joint venture with Americas Silver Corporation on property that contains tailings with low grade gold and silver from the Drumlummon Mine in Montana. Spruce Ridge and its joint venture partner, a private investor group, are currently drilling magnetic and EM anomalies in a complex of ultramafic and mafic intrusive rocks that have been interpreted as prospective for nickel mineralization, on the optioned Crawford property 45 kilometres north of Timmins, Ontario.

Colin Bowdidge, Ph.D, P.Geo., a “Qualified Person” as defined in National Instrument 43-101, and a director of the Company, has prepared and/or reviewed the technical contents of this press release.

For further information please contact:

John Ryan, President and CEO
Spruce Ridge Resources Ltd.
Phone: 519-822-5904
Email: spruceridgeresources@gmail.com

Cautionary Statement

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

The foregoing information may contain forward-looking statements relating to the future performance of Spruce Ridge Resources Ltd. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially from the Company’s plans and expectations. These plans, expectations, risks and uncertainties are detailed herein and from time to time in the filings made by the Company with the TSX Venture Exchange and securities regulators. Spruce Ridge Resources Ltd. does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Spruce Ridge Resources Ltd.

ReleaseID: 534003

Company Also Reaches Pricing Consensus with Big Box for Private Label Version of Its Genultimate Test Strip Alleviating Remaining Obstacle

LOS ANGELES, CA / ACCESSWIRE / January 30, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company’s current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses.

Today the company announces that they have received formal FDA CDRH notification that the GenChoice! test strip 510K application submission has been accepted and routed for review. That submission has been assigned ”K” number, K190108, which will follow the application through the review and clearance processes. This application and K number assignment, delayed by weeks due to the US government shutdown, has been released for progression.

Keith Berman, CEO of DECN stated, ”Our GenChoice! 510K application is now being examined by the CDRH reviewers and investigators with whom the company has closely worked over the last eight years. Prior to this 510K submission we painstakingly examined all of our comprehensive clinical testing data, and the extensive testing protocols and results. We reached a satisfactory comfort level with the collective information; leading to the resultant application submission. The GenChoice! product clearly meets or exceeds all current FDA and ISO standards. Now that the GenChoice! is under FDA review and a ”K” number assigned, the previously announced international GenChoice! product launch will proceed in select International markets.”

DECN simultaneously announces that discussions with the ”Big Box” retailer for the private label manufacture of a house brand product, has progressed to the next step. The recently communicated initial pricing obstacle has been overcome and the companies are now expecting a move forward. More information regarding this agreement will be communicated in the coming days.

Mr. Berman concluded, ”DECN is now shifting into a higher gear. Our GenChoice! test strip is in review and we have high hopes for its success; our first large private label agreement is advancing; and, we are now pivoting to the GenUltimate! 4Pets launch in the next two weeks. In fact the ”G 4Pets” product has been assigned a February manufacturing slot. We are also very excited about the beginning of the scheduled clinical trials for our GenUltimate! TBG.”

ABOUT DECISION DIAGNOSTICS CORP

Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $12 billion at-home testing market.

FORWARD LOOKING STATEMENTS

This release contains the company’s forward-looking statements which are based on management’s current expectations and assumptions as of January 29, 2019, regarding the company’s business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:

Decision Diagnostics Corp.
Keith Berman (805) 446-2973
info@decisiondiagnostics.com
www.genultimate.com
www.petsureteststrips.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.

ReleaseID: 533906

LONDON, UK / ACCESSWIRE / January 30, 2019 / CBD Oil is one of the fastest growing wellness supplements has now come under an EFSA (European Food Standard Agency) classification which could mean CBD Oil will no longer be legally sold within the UK.

Healthspan, the UK’s leading health supplement supplier, who was one of the early adopters to launch CBD Oil capsules, says a change to the status of CBD Oil was published Friday (18th January) by EFSA which has raised some question marks over CBD’s continued status as a legal food supplement in the UK. 

CBD oil has seen a meteoric rise in sales with the Cannabis Trade Association UK saying the number of users has skyrocketed from 125,000 to 250,000 users.

Dr Sarah Brewer advises.  ”The new classification by EFSA is for regulatory/technicality reasons and not for safety reasons. Given that there is some uncertainty on the future free availability of CBD supplement, I’d recommend that people who find it beneficial for well-being continue as previously by ordering from a trusted supplier and continuing to take their CBD Oil.”

So, what has changed?

The entry on the Novel Foods register changed regarding the classification of CBD Oil. The entry for “Cannabinoids” now states ‘extracts of Cannabis sativa L. and derived products containing cannabinoids are considered novel foods as a history of consumption has not been demonstrated. This applies to both the extracts themselves and any products to which they are added as an ingredient (such as hemp seed oil).” This means that CBD supplements are now deemed to be novel food in Europe. (Search “cannabinoids” here: http://ec.europa.eu/food/safety/novel_food/catalogue/search/public/index.cfm)

What is Novel Food? (https://ec.europa.eu/food/safety/novel_food_en)

Novel Food is defined as food that had not been consumed to a significant degree by humans in the EU before 15 May 1997, when the first regulation on novel food came into force. Examples of Novel Food include new sources of vitamin K (menaquinone) or extracts from existing food (Antarctic Krill oil rich in phospholipids from Euphausia superba), agricultural products from third countries (chia seeds, noni fruit juice), or food derived from new production processes such as UV-treated food (milk, bread, mushrooms and yeast).

The underlying principles underpinning Novel Food in the European Union are that Novel Foods must be:

Safe for consumers
Properly labelled, so as not to mislead consumers
If novel food is intended to replace another food, it must not differ in a way that the consumption of the Novel Food would be nutritionally disadvantageous for the consumer.
Pre-market authorisation of Novel Foods on the basis of an evaluation in line with the above principles is necessary.

Why the change?

As there is no direct safety risk related to CBD Oil, opinion is that this is a political measure taken by the States* and it is an issue of having missed a ‘processing step’ as companies/industry was under the impression (based on earlier EFSA wording) that CBD would not class as a Novel food.

As of today, (29th January) there is no Food Standards Authority (FSA) official ruling but FSA wording implies that products will need to be withdraw from market very soon which means there will be no derogation period allowing the industry to apply for the Novel Food Approvals.

In the meantime, companies such as Healthspan and the industry of CBD growers, processors and sellers are gathering the data to do the Novel Food submission however this process can take time.

Rollo de Sausmarez, Healthspan’s Director of New Product Marketing & Development says, “Next steps are getting CBD an Approved Novel Food Status. Many things have been deemed safe by passing a safety assessment under the Novel Food Regulation – e.g. Chia seeds, Krill Oil, Vitamin K. This process takes about a year, and CBD manufacturers and brands will be pursuing this approach. All over Europe the local food safety authorities will be considering their approach, in each member state and in time will publish their stance. 

“Healthspan will continue to work with relevant bodies such as EFSA, FSA and the CTA (Cannabis Trade Association).”

In terms of how long this will take the FSA yesterday stated that they will begin working with local authorities to identify and begin to remove products that do not comply with the Novel Food Regulations (EU) 2015/2283. This may take a period of time and as yet there have been no formal instructions from the EFSA and the FSA.

Various trade organizations including the UK based Cannabis Trades Association (CTA), British Hemp Association (BHA), European Industrial Hemp Association (EIHA) as well as individual businesses will be talking to EFSA and the FSA about these new regulations.

What next?

Suppliers will be working to get CBD an Approved Novel Food Status. Many things have been deemed safe by passing a safety assessment under the Novel Food Regulation – e.g. Chia seeds, Krill Oil, Vitamin K. This process takes about a year, and CBD manufacturers and brands will be pursuing this approach.

Can I still buy CBD in the UK? 

The short answer is ‘yes for now’ but with the new FSA ruling it is recommended people do consider stocking up.

Dr Sarah Brewer summarises, “With all the change taking place there is still a great deal of misunderstanding and misleading information about CBD Oil on the market. Making sure you buy CBD Oil from a reputable supplier who is a member of the Cannabis Trade Association is important also looking out for products advertising whole plant extract percentage of CBD, as opposed to the level of CBD in mgs in the product.”

Also, in June 2018, The World Health Organization carried out a review of CBD and findings

Stated that “CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications.”

The WHO report did state that there is ‘unsanctioned medical use of CBD based products’, but the report did underline that CBD is well tolerated and has a good safety profile. “Across a number of controlled and open label trials CBD of the potential therapeutic effects of CBD it is generally well tolerated, with a good safety profile.”

(https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf)

For further information contact Mars Webb @ Mars Webb PR

Email: mars@marswebbpr.co.uk /pressoffice@healthspan.co.uk

Tel: 07717718063

Notes to Editors:

-Spokesperson Dr Sarah Brewer available via email only.

– *Each and every country has a legal right to have changes made to the Novel Food Register if they can get a majority to agree. The five initial petitioners were Germany, Italy, France, UK and The Netherlands. They managed to gain support from 17-member states.

SOURCE: Healthspan

ReleaseID: 534002

VANCOUVER, BC / ACCESSWIRE / January 30, 2019 / Subscribe Technologies Inc. (CSE: SAAS, OTCQB: SRBBF, Frankfurt: 6GQ) (“Subscribe” or “the Company”) is pleased to announce the Company is developing WebinarIgnition LITE to be added to the WordPress Plugin Directory.

WebinarIgnition is a fully developed, 100% owned website plugin for WordPress, enabling users to easily setup and charge viewers for watching videos and webinar presentations. It is our belief that releasing a Lite version of the plugin will introduce our webinar technology to a much larger WordPress focused audience.

Features included with the Lite version will include single website use with live webinar mode only and minimal customization features. Various paid upgrade options and promotional links will also be included throughout the freemium WebinarIgnition Lite plugin.

According to the Content Marketing Institute, 58% of marketers use webinars for promotion and about 32% of them think webinar marketing will be critical to their success this year. Webinar marketing is a technique using an online seminar to connect with a wider audience and promote your business. The term “webinar” comes from the words “web seminar”. Typical webinar offerings include live interviews, seminars, conferences, demonstrations, counseling and therapy among many other uses by users providing premium video content.

For its part, WordPress is more than a piece of website management software, it’s a global culture. WordPress is the top Content Management System (“CMS”) in the world with 60% of the CMS market, powering an estimated 27% of websites on the internet, and 30% of the top 10 million websites around the world with over 75 million installs globally to date. WordPress developer camps (“WordCamps”) are held globally with the total number of WordCamps to ever take place growing rapidly – currently at more than 930 organized in total, held in 71 cities, 65 countries, on 6 continents, all over the globe. Meanwhile, over 1.25 Billion total plugin downloads have occurred from the WordPress Directory so far and there are over 50,000 WordPress plugins in the official directory, with new ones being added daily.

President and CEO Mr. Paul Dickson states, “I’ve personally been using WordPress from its beginning and watched it evolve into this amazing tool for content marketers, publishers and businesses. I feel our product will be welcomed by the WordPress community as we believe there are few options that compare with our Webinar Ignition product.”

About Software as a Service (SaaS)

Software as a Service is a fast emerging, cloud based, online business model allowing companies to offer their unique software services and scale their customer base exponentially, worldwide, from any location.

About WebinarIgnition

WebinarIgnition is the most flexible platform for creating professional live & automated webinar funnels.

WebinarIgnition Features Customizable Registration, Confirmation, Live & Replay Pages, Live Video Feed Integration (Including Google Hangouts), Email & Text Message Reminders, Q&A / Chat Integration, Sales and Conversion Tracking and No Monthly Fee. The platform also integrates with all major email platforms including MailChimp, GetResponse, Aweber, iContact, and SendReach.

Visit: www.webinarignition.com

About Subscribe Technologies Inc.

Subscribe Technologies (CSE: SAAS, OTCQB: SRBBF, Frankfurt: 6GQ) develops, partners with, acquires, and invests in cloud based software as a service (SaaS) solutions for small and medium sized enterprises (SMEs).

To learn more about Subscribe Technologies, please visit www.subscribetech.com.

On Behalf of the Board,
Paul Dickson
President & CEO

Contact:

Patrick Butler
VP Shareholder Communications
pbutler@creeksidecommunicationsltd.com
Tel: 1 (855) 439 7227

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of Subscribe Technologies Inc. The forward-looking information is based on certain key expectations and assumptions made by the company’s management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the company can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and the company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.

SOURCE: Subscribe Technologies Inc.

ReleaseID: 533977

VANCOUVER, BC / ACCESSWIRE / January 30, 2019 / TriMetals Mining Inc. (TSX: TMI) (OTCQX: TMIAF), (”TMI” or the ”Company”) announces that Mr. Eric Edwards has submitted his resignation as TMI’s President and Chief Executive Officer and from TMI’s Board of Directors effective January 31, 2019.

The Board of Directors of TMI are grateful for Mr. Edwards’ achievements while at TMI. He joined TMI in January 2018 and was successful in streamlining and focusing the Company. In the past year, the Company has signed a divestiture agreement for the Escalones Copper Project in Chile, received the award notification regarding expropriation of the Malku Khota project in Bolivia for US$28 million (including interest), and has minimized administration and overhead costs. The Company no longer has any secured debt after having recently completed a conversionof US$1.7 million in secured debt into common shares.

Mr. Matias Herrero has been appointed as Interim Chief Executive Officer effective February 1, 2019. Mr. Herrero previously served as Chief Financial Officer of the Company from July 2012 through October 2017. Mr. Herrero is a CA, CPA, with 14 years of mining industry experience and was involved with TMI in the Malku Khota arbitration proceedings from the beginning.

Mr. Van Doorn, Chairman of the Company, stated: ”TMI welcomes Mr. Herrero back to the Company where his knowledge of our claim against Bolivia will be very valuable and we expect Mr. Herrero to be able to continue with the cost savings measures that Mr. Edwards has implemented.”

About TriMetals Mining Inc.

TriMetals Mining Inc. (TSX: TMI and OTCQX: TMIAF) is a growth-focused gold exploration company creating value through the exploration and development of the near-surface Gold Springs gold-silver project in mining-friendly Nevada and Utah, U.S.A.

The Company’s Class B shares are listed on the Toronto Stock Exchange under ”TMI.B” and have no interest in the properties or assets of the Company other than the collective entitlement to 85% of the net cash, if any (after deducting all costs, taxes and expenses and the amount due to a third party that funded the costs of the arbitration), received by the Company from an award or settlement in relation to South American Silver’s arbitration proceeding against Bolivia for the expropriation of the Malku Khota project in 2012.

TriMetals Mining Inc. Contact:

Robert van Doorn
Chairman

Forward-looking Statements

Certain statements contained herein constitute ”forward-looking information” under applicable Canadian securities laws (”forward-looking statements”). Forward-looking statements look into the future and provide an opinion as to the effect of certain events and trends on the business. Forward-looking statements may include words such as ”shall”, ”will”, and similar expressions. These forward-looking statements are based on current expectations and entail various risks and uncertainties. Actual results may materially differ from expectations if known and unknown risks or uncertainties affect our business or if our estimates or assumptions prove inaccurate. Factors that could cause results or events to differ materially from current expectations expressed or implied by the forward-looking statements, include, but are not limited to, risks more fully described in the Company’s Annual Information Form and continuous disclosure documents, which are available on SEDAR at www.sedar.com.

Readers are cautioned not to place undue reliance on the forward-looking statements contained in this press release. Except as required by law, the Company assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Unless otherwise indicated, forward-looking statements in this press release describe the Company’s expectations as of the date hereof.

Contact information:

kruby@trimetalsmining.com
604.639.4527

SOURCE: TriMetals Mining Inc.

ReleaseID: 533921

WESTON, FL / ACCESSWIRE / January 30, 2019 / Bayside Corporation (OTCQB: BYSD) (”Bayside or the ”Company”), announced that its CEO, Justin Frankel, was recently interviewed by Sasha Hodder on the popular Bitcoin and Crypto Law Podcast HODLcast. During the podcast, Justin and Sasha talk about the Bitcoin ATM business and the regulatory and banking landscape shaping the industry. They also discuss how the price of Bitcoin impacts customer behavior and some of the challenges and opportunities that come with operating Bitcoin ATMs.

You can listen to the interview on iTunes, Soundcloud or at www.sashahodler.com.

About Bayside Corp

Bayside Corp. is an American corporation that trades publicly under the symbol ‘BYSD’. At Bayside Corp., we believe that emerging technologies will create new opportunities for generations to come. Crypto-assets and blockchain technology will fundamentally impact a broad range of industries such as financial services, digital rights management, and computer processing and programming, along with many others. Our goal is to become the premier provider of infrastructure in this new and exciting industry. For additional information on the Company visit our website at: http://www.baysidecorp.com.

Forward-Looking Statements:

This press release may contain projections and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such projections or statement reflect the company’s current views with respect to future events and financial performance. No assurances can be given, however, that these events will occur or that such projections will be achieved and that actual results could differ materially from those projected. Important factors that could cause actual results to differ from those projected are decreases in oil and gas prices or decreases in oil and gas production. The company’s actual results could differ materially from those discussed herein. Forward-looking statements are subject to risks and uncertainties, including, but not limited to, government regulation, taxation, spending, competition, general economic conditions and other risk factors which could cause actual results to differ materially from those projected or implied in the forward-looking statements.

Company Contact:

Info@baysidecorp.com

SOURCE: Bayside Corporation

ReleaseID: 533961

TORONTO, ON / ACCESSWIRE / January 30, 2019 / Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), has demonstrated no tumour recurrence or presence of disease at the 270 day clinical and cystoscopy assessment.

The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints.

Patient five and six have demonstrated no tumour recurrence or presence of disease at the 90, 180 and now 270 days post treatment clinical and cystoscopy assessment, marking a new achievement for the Company.

Patient five and six were enrolled and treated in the Study at the Therapeutic Dose (0.70 mg/cm2). Theralase’s Anti-Cancer Treatment involved the intravesical instillation of a water-based solution of Theralase’s lead anti-cancer PDC, TLD-1433, via a catheter inserted through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours. The bladder was then drained of the solution, flushed with sterile water to remove non-absorbed solution and refilled with sterile water via a cystoscope. A fibre optic assembly, comprising a Laser Emitter used to emit laser light and a proprietary Dosimetry System used to detect laser light, were then used to activate TLD-1433 resident in the NMIBC tumours.

Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer of Theralase stated, “This new data from patient six mirrors the 270 days Complete Response (“CR”) efficacy data observed in patient five at the same time interval. This evidence further bolsters our understanding that even a single treatment of Theralase’s Photo Dynamic Therapy (“PDT”) is able to lead to CR at 270 days post treatment for patients presenting with Bacillus Calmete Guérin (“BCG”)-Unresponsive NMIBC. This illustrates the enormous opportunity that awaits Theralase in the treatment of NMIBC. For NMIBC, a CR post treatment has recently been defined by the FDA as the definitive endpoint for a single-arm intravesical study for patients who present with BCG-Unresponsive Carcinoma In-Situ (“CIS”) disease, with or without resected papillary tumours. In the Health Canada approved Phase II NMIBC clinical study, the Company is providing two treatment procedures (therapeutic procedure at Day 0 and maintenance procedure at Day 180). The latest data on patient five and six is extremely encouraging, demonstrating that CR at 270 days post-treatment is achievable in the elimination of NMIBC after only one PDT treatment procedure. If the efficacy results are able to be demonstrated at 12 months post-treatment, in a larger patient population, conducted in a well-designed Phase II NMIBC clinical study, then the Theralase Anti-Cancer Technology has the potential to be the next gold standard in the treatment of NMIBC. The Theralase Anti-Cancer Technology is also multi-faceted, in that the technology is able to be adapted to the treatment of additional cancer indications, if successfully validated in independent clinical studies. Pending successful commencement of the Phase II NMIBC clinical study, the Company plans to investigate the commencement of an additional Phase Ib clinical study for a new cancer indication.”

The Phase II NMIBC Clinical Study, entitled, “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer or Patients Who are Intolerant to BCG Therapy” will utilize the Therapeutic Dose (0.70 mg/cm2) of TLD-1433 and will focus on the enrollment and treatment of approximately 100 BCG-Unresponsive NMIBC patients in approximately 20 clinical sites located in Canada, the US and internationally, with a primary endpoint of efficacy and a secondary endpoint of safety.

The endpoints of the Phase II NMIBC Clinical Study will be:

Primary (Efficacy) – Evaluated by CR in patients with CIS with or without resected papillary disease at 90 days post-treatment with duration of CR evaluated at 360 days post-treatment.

Patient CR is defined as at least one of the following:

1) Negative cystoscopy and negative (including atypical) urine cytology
2) Positive cystoscopy with biopsy-proven benign or low-grade NMIBC
3) Negative cystoscopy with malignant urine cytology, if cancer is found in the upper tract or prostatic urethra and random bladder biopsies are negative

Secondary (Safety) – Evaluated by the incidence and severity of Adverse Events (“AEs”) Grade 4 or higher that do not resolve within 360 days post-treatment; whereby:

Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening or disabling and Grade 5 = Death

Proposed Phase II Clinical Study Treatment Plan:

About Theralase® Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.

Additional information is available at www.theralase.com and www.sedar.com

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company’s proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to: successfully fund and complete a Phase II NMIBC clinical study, secure the requisite regulatory approvals to commence a Phase II NMIBC clinical study and implement its development plans. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

1.866.THE.LASE (843-5273)
416.699.LASE (5273)
info@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 533946